Published in Gynecol Oncol on February 01, 2005
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism. Chem Biol (2007) 1.65
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 1.45
BCL-XL mediates the strong selective advantage of a 20q11.21 amplification commonly found in human embryonic stem cell cultures. Stem Cell Reports (2013) 1.09
Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J Biol Chem (2009) 1.08
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One (2010) 1.06
Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem (2011) 1.05
Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS One (2011) 1.01
AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol Ther (2012) 1.01
BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cells. PLoS One (2011) 0.97
A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer (2011) 0.96
Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene (2014) 0.94
Alteration of cellular behavior and response to PI3K pathway inhibition by culture in 3D collagen gels. PLoS One (2012) 0.92
Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One (2012) 0.91
The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1. Mol Med (2011) 0.88
Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells. BMC Cancer (2011) 0.88
Control of cellular Bcl-xL levels by deamidation-regulated degradation. PLoS Biol (2013) 0.86
Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS One (2014) 0.85
Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY) (2016) 0.84
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant (2009) 0.84
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. PLoS One (2012) 0.83
NOXA-induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to cisplatin. PLoS One (2012) 0.83
Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells. Oncotarget (2016) 0.83
The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer. Sci Rep (2016) 0.83
Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma. Br J Cancer (2013) 0.81
Alpha-tocopheryl succinate potentiates the paclitaxel-induced apoptosis through enforced caspase 8 activation in human H460 lung cancer cells. Exp Mol Med (2009) 0.80
Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas. PLoS One (2014) 0.80
Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition? Front Oncol (2016) 0.79
High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicin. Oncotarget (2016) 0.77
DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer (2015) 0.76
Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy. Cancer Chemother Pharmacol (2008) 0.76
Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP. Int J Oncol (2017) 0.75
Dynamic Bcl-xL (S49) and (S62) Phosphorylation/Dephosphorylation during Mitosis Prevents Chromosome Instability and Aneuploidy in Normal Human Diploid Fibroblasts. PLoS One (2016) 0.75
Pristimerin overcomes adriamycin resistance in breast cancer cells through suppressing Akt signaling. Oncol Lett (2016) 0.75
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cells. Oncotarget (2016) 0.75
ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer. Neoplasia (2017) 0.75
Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res (2016) 0.75
Bcl-xL overexpression and its association with the progress of tongue carcinoma. Int J Clin Exp Pathol (2014) 0.75
Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis. Cancer Cell Int (2017) 0.75
Gender differences in time spent on parenting and domestic responsibilities by high-achieving young physician-researchers. Ann Intern Med (2014) 4.76
Sex differences in attainment of independent funding by career development awardees. Ann Intern Med (2009) 4.62
Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol (2006) 3.79
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood (2012) 3.44
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys (2006) 3.40
A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB activation. EMBO J (2007) 2.72
Gender differences in salary in a recent cohort of early-career physician-researchers. Acad Med (2013) 2.68
Gender differences in the salaries of physician researchers. JAMA (2012) 2.66
Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2007) 2.33
Wnt10b inhibits development of white and brown adipose tissues. J Biol Chem (2004) 2.32
A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res (2011) 2.24
Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res (2004) 2.20
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol (2002) 2.10
CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci U S A (2006) 1.96
Similarities and differences in the career trajectories of male and female career development award recipients. Acad Med (2011) 1.81
Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer (2007) 1.76
Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol (2006) 1.75
Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys (2010) 1.67
Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell (2009) 1.67
The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer (2007) 1.64
CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology (2002) 1.62
(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia (2006) 1.55
RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat (2005) 1.49
Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery (2007) 1.47
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci U S A (2009) 1.43
High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer (2005) 1.43
Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res (2005) 1.41
Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg (2005) 1.39
Work-life balance in academic medicine: narratives of physician-researchers and their mentors. J Gen Intern Med (2013) 1.37
Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorder. Cancer Cell (2009) 1.36
alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol (2002) 1.34
External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys (2006) 1.33
Mentoring and the career satisfaction of male and female academic medical faculty. Acad Med (2014) 1.31
Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science (2011) 1.30
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy. Breast Cancer Res Treat (2005) 1.30
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res (2013) 1.20
Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest (2002) 1.17
Features predicting sentinel lymph node positivity in Merkel cell carcinoma. J Clin Oncol (2011) 1.16
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer (2013) 1.16
Evaluation of four techniques using intensity-modulated radiation therapy for comprehensive locoregional irradiation of breast cancer. Int J Radiat Oncol Biol Phys (2010) 1.13
MALT1 protease: a new therapeutic target in B lymphoma and beyond? Clin Cancer Res (2011) 1.12
Cognitive-behavioral intervention for distress in patients with melanoma: comparison with standard medical care and impact on quality of life. Cancer (2003) 1.10
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat (2010) 1.10
Role of radiotherapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys (2010) 1.10
Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol (2007) 1.09
Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys (2007) 1.07
Toxicity of radiotherapy in patients with collagen vascular disease. Cancer (2008) 1.06
Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol (2014) 1.06
From MALT lymphoma to the CBM signalosome: three decades of discovery. Cell Cycle (2011) 1.05
Ginger inhibits cell growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement Altern Med (2007) 1.04
Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol (2006) 1.04
The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J Biol Chem (2010) 1.04
Is there a dose-response relationship for heart disease with low-dose radiation therapy? Int J Radiat Oncol Biol Phys (2012) 1.04
Planning the breast tumor bed boost: changes in the excision cavity volume and surgical scar location after breast-conserving surgery and whole-breast irradiation. Int J Radiat Oncol Biol Phys (2006) 1.03
Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment. Future Oncol (2011) 1.03
Stroke rates and risk factors in patients treated with radiation therapy for early-stage breast cancer. J Clin Oncol (2006) 1.03
Glucose deprivation activates AMPK and induces cell death through modulation of Akt in ovarian cancer cells. Gynecol Oncol (2011) 1.02
Analytic morphometric assessment of patients undergoing colectomy for colon cancer. J Surg Oncol (2013) 1.02
Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol (2007) 1.02
Thrombin-dependent NF-{kappa}B activation and monocyte/endothelial adhesion are mediated by the CARMA3·Bcl10·MALT1 signalosome. J Biol Chem (2010) 1.01
Conservative management of Paget disease of the breast with radiotherapy: 10- and 15-year results. Cancer (2003) 1.01
Physician and patient attitudes towards complementary and alternative medicine in obstetrics and gynecology. BMC Complement Altern Med (2008) 1.01
Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer (2003) 1.00
Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol (2006) 0.98
A Mixed-Methods Investigation of the Motivations, Goals, and Aspirations of Male and Female Academic Medical Faculty. Acad Med (2016) 0.98
The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery (2004) 0.96
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. Am J Clin Oncol (2007) 0.96
Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 Cases. Sarcoma (2013) 0.95
Gender differences in resources and negotiation among highly motivated physician-scientists. J Gen Intern Med (2014) 0.95
Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer (2009) 0.94
Validation of statistical predictive models meant to select melanoma patients for sentinel lymph node biopsy. Ann Surg Oncol (2011) 0.94
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. Invest New Drugs (2008) 0.93
β-Arrestin-1 deficiency protects mice from experimental colitis. Am J Pathol (2013) 0.93
Rate of freeze alters the immunologic response after cryoablation of breast cancer. Ann Surg Oncol (2009) 0.93
Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 0.93
Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys (2003) 0.93
Constitutively active NFkappa B is required for the survival of S-type neuroblastoma. J Biol Chem (2002) 0.91
Correlates of mammogram density in southwestern Native-American women. Cancer Epidemiol Biomarkers Prev (2003) 0.90
Defective apoptosis underlies chemoresistance in ovarian cancer. Adv Exp Med Biol (2008) 0.90
Aberrant Huntingtin interacting protein 1 in lymphoid malignancies. Cancer Res (2007) 0.90
Significance of multiple lymphatic basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol (2006) 0.90
Long-term results of conservative surgery and radiotherapy for ductal carcinoma in situ using lung density correction: the University of Michigan experience. Breast J (2007) 0.89
The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy, and apoptosis in ovarian cancer cells. Gynecol Oncol (2009) 0.89
The identification of empirically derived cancer patient subgroups using psychosocial variables. J Psychosom Res (2004) 0.89
Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer (2011) 0.88
Accelerated partial breast irradiation: what is dosimetric effect of advanced technology approaches? Int J Radiat Oncol Biol Phys (2009) 0.87
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer. Int J Radiat Oncol Biol Phys (2009) 0.87
Finally, MALT1 is a protease! Nat Immunol (2008) 0.87
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer (2007) 0.87